Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Dec 2017 · 1 min read
In brief
In brief
This study used whole exome sequencing to identify 65 coding mutations across four neuroblastoma tumors, including 43 previously unreported variants. High-risk stage 4 tumors showed mutations in genes regulating immune function and metastasis, providing insights into the genetic heterogeneity of this deadly pediatric cancer.
Written by the GCMD Library team from the article.
Statements in this article
Neuroblastoma accounts for approximately 15% of childhood deaths from cancer.
The five-year survival for patients with high-risk stage 4 neuroblastoma has not improved in two decades.
Whole exome sequencing identified 43 mutations that had not been reported previously among four neuroblastoma tumors.
One mutation was present in two of the four tumors analyzed.
Whole exome sequencing corroborated 22 mutations that were reported previously.
No single mutation occurred in all four tumors or in all stage 4 tumors.
Three of the four tumors harbored genes with CADD scores ≥20, indicative of mutations associated with human pathologies.
The average depth of coverage ranged from 39.68 to 90.27, with >99% sequences mapping to the genome.
The three stage 4 tumors contained mutations in genes encoding protein products that regulate immune function or cell adhesion and tumor cell metastasis.